UNH Q1 Reversal: Can Margin Expansion Hold Next Quarter?
UnitedHealth rose 2.17% to $353 as Argus Research upgraded the stock and Morgan Stanley declared Q1 results mark a "formal reversal," with institutional consensus building around margin-expansion-driven upside. Markets are reassessing whether elevated medical loss ratios have peaked, with SeekingAlpha publishing same-day support for the sustained margin expansion thesis. Technically, $350 is key support; a path toward $370–$400 revaluation sharpens if Q2 data confirms AI-driven cost reduction — but can the reversal narrative survive if loss ratios rebound?